IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China
Ren, Qian1; Han, Xueyao1; Tang, Yong2; Zhang, Xiuying1; Zou, Xiantong1; Cai, Xiaoling1; Zhang, Simin1; Zhang, Lihua1; Li, Hechao1; Ji, Linong1
关键词Glibenclamide Pharmacogenetics SNP Type 2 diabetes
刊名DIABETOLOGIA
2014-04-01
DOI10.1007/s00125-013-3146-z
57期:4页:746-753
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]GENOME-WIDE ASSOCIATION ; THERAPEUTIC RESPONSE ; INSULIN-RESISTANCE ; SECONDARY FAILURE ; ALLELIC VARIANTS ; FASTING GLUCOSE ; COMMON VARIANTS ; INCREASED RISK ; E23K VARIANT ; CYP2C9
英文摘要

Aims/hypothesis The aim of this study was to investigate whether genetic variance can influence the efficacy of glibenclamide in patients with type 2 diabetes.

A total of 747 patients with type 2 diabetes was enrolled from the Xiaoke Pills Clinical Trial, which is a double-blind, randomised controlled trial. All the patients had been treated with glibenclamide for 48 weeks, with strict drug dose adjustment and data collection. Treatment failure was confirmed when patients reached the criteria for terminating their participation in the study (fasting blood glucose level a parts per thousand yen7.0 mmol/l on two consecutive tests 4 weeks after reaching the pre-set maximal dose or maximal tolerated dose). Using this cohort, we tested 44 single-nucleotide polymorphisms (SNPs) in 27 gene regions. The genes in our study were involved in the metabolism of sulfonylureas, islet beta cell function, insulin resistance and beta cell growth and differentiation. A logistic regression model was used to evaluate the relationship between genetic variants and treatment failure over a period of 48 weeks.

We found that no SNP reached the significance level of p < 0.00125 if Bonferroni correction was performed for multiple testing in the logistic regression model used in this pharmacogenetic study. Participants with the minor allele C of rs10811661 in CDKN2A/CDKN2B showed a significantly greater reduction in fasting blood glucose (TT vs TC vs CC: 9.3% (0-20.0%) vs 9.2% (0.9-20.5%) vs 12.7% (5.2-24.4%), p = 0.008) after the initial 4 weeks of treatment independent of age, sex and BMI. There was a significant difference in beta cell function among carriers of different genotypes of rs10811661.

Our study demonstrated that the CDKN2A/CDKN2B gene may be nominally associated with the efficacy of glibenclamide, and that CDKN2A/CDKN2B is associated with beta cell function.

语种英语
WOS记录号WOS:000332600700013
项目编号2012AA02A509 ; 2006AA02A409 ; 81000334 ; 2006CB503903
资助机构National High Technology Research and Development Program 863 program ; Guangzhou Zhongyi Pharmaceutical ; National Natural Science Fund ; National Basic Research Program of China 973 program
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60556
专题北京大学第二临床医学院
作者单位1.Hebei Peoples Hosp, Dept Endocrinol & Metab, Hebei, Peoples R China
2.Peking Univ, Dept Endocrinol & Metab, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Ren, Qian,Han, Xueyao,Tang, Yong,et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China[J]. DIABETOLOGIA,2014,57(4):746-753.
APA Ren, Qian.,Han, Xueyao.,Tang, Yong.,Zhang, Xiuying.,Zou, Xiantong.,...&Ji, Linong.(2014).Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.DIABETOLOGIA,57(4),746-753.
MLA Ren, Qian,et al."Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China".DIABETOLOGIA 57.4(2014):746-753.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ren, Qian]的文章
[Han, Xueyao]的文章
[Tang, Yong]的文章
百度学术
百度学术中相似的文章
[Ren, Qian]的文章
[Han, Xueyao]的文章
[Tang, Yong]的文章
必应学术
必应学术中相似的文章
[Ren, Qian]的文章
[Han, Xueyao]的文章
[Tang, Yong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。